MiNK Therapeutics, Inc. (NASDAQ:INKT) stock soared 200% after the company announced a complete remission in a patient with metastatic testicular cancer following treatment with its allogeneic iNKT cell therapy, agenT-797.
July 11, 2025 - 14:53
By Pharos Investment Advisors Comments are Off
MiNK Therapeutics, Inc. (NASDAQ:INKT) stock soared 200% after the company announced a complete remission in a patient with metastatic testicular cancer following treatment with its allogeneic iNKT cell therapy, agenT-797.
Regulated by Hellenic Capital Market Commission
with Registration Number 5/700/10.12.2014

Copyright 2023©. All Rights Reserved